New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 24, 2014
08:11 EDTLGND, TGTXTG completes global license agreement with Ligand for IRAK4
TG Therapeutics (TGTX), announced an agreement with Ligand Pharmaceuticals (LGND) to license exclusive global rights to develop and commercialize Ligand's IRAK4 inhibitor research program. The IRAK4 program is currently in pre-clinical development. Under the terms of the agreement, Ligand will receive an up-front licensing fee of 125k unregistered shares of TG Therapeutics' common stock. In addition, TG will make development and sales-based milestone payments and will pay a tiered, mid-to-high single digit royalty on net sales.
News For TGTX;LGND From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
11:32 EDTLGNDLigand reports Pfizer receives EU marketing authorization for Duavive
Ligand Pharmaceuticals (LGND) announced that its partner Pfizer (PFE) has received EU marketing authorization for DUAVIVE from the European Commission. In the EU, DUAVIVE is indicated for the treatment of estrogen deficiency symptoms in postmenopausal women with a uterus for whom treatment with progestin-containing therapy is not appropriate. Ligand will be entitled to a milestone payment following Pfizer obtaining pricing of DUAVIVE in a major European market, the company stated.
December 10, 2014
10:33 EDTTGTXTG Therapeutics price target raised to $33 from $25 at Roth Capital
December 9, 2014
11:15 EDTTGTXTG Therapeutics announces data of TG-1101 in combination with TGR-1202
Subscribe for More Information
December 8, 2014
13:45 EDTTGTXTG Therapeutics says TG-1101 well tolerated in Phase 2 study
Subscribe for More Information
December 7, 2014
16:16 EDTTGTXTG Therapeutics announces results from Phase l study of TGR-1202
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use